A core outcome set for clinical trials of chemoradiotherapy interventions for anal cancer (CORMAC): a patient and health-care professional consensus.
Authors
Fish, RebeccaSanders, C
Adams, R
Brewer, Julie
Brookes, S
DeNardo, Jill
Kochhar, Rohit
Saunders, Mark P
Sebag-Montefiore, D
Williamson, P
Renehan, Andrew G
Affiliation
Division of Cancer Sciences, School of Medical Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UKIssue Date
2018
Metadata
Show full item recordAbstract
Chemoradiotherapy is the primary treatment for patients with squamous cell carcinoma of the anus, but variations in the reported outcomes have restricted between-study comparisons. Treatment-related morbidity is considerable; however, no trial has comprehensively quantified long-term side-effects or quality of life. Therefore, we established the first international health-care professional and patient consensus to develop a core outcome set, using the Core Outcome Measures in Effectiveness Trials method. We used the results from our previous systematic review and combined them in this Review with patient interviews to derive a comprehensive list of outcomes, followed by a two-round Delphi survey completed by 149 participants (55 patients and 94 health-care professionals) from 11 countries. The Delphi results were discussed at a consensus meeting of health-care professionals and patients. Agreement was reached on 19 outcomes across four domains: disease activity, survival, toxicity, and life impact. Implementation of the Core Outcome Research Measures in Anal Cancer (CORMAC) set in future trials will serve as a framework to achieve standardisation, facilitate selection of health-area-specific evaluation tools, reduce redundancy of outcome lists, allow between-study comparisons, and ultimately enhance the relevance of trial findings to health-care professionals, trialists, and patients.Citation
Fish R, Sanders C, Adams R, Brewer J, Brookes S, DeNardo J, et al. A core outcome set for clinical trials of chemoradiotherapy interventions for anal cancer (CORMAC): a patient and health-care professional consensus. Lancet Gastroenterol Hepatol. 2018 Dec;3(12):865-73.Journal
Lancet Gastroenterol HepatolDOI
10.1016/S2468-1253(18)30264-4PubMed ID
30507470Additional Links
https://dx.doi.org/10.1016/S2468-1253(18)30264-4Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1016/S2468-1253(18)30264-4
Scopus Count
Collections
Related articles
- Core outcome research measures in anal cancer (CORMAC): protocol for systematic review, qualitative interviews and Delphi survey to develop a core outcome set in anal cancer.
- Authors: Fish R, Sanders C, Williamson PR, Renehan AG
- Issue date: 2017 Nov 22
- International consensus to define outcomes for trials of chemoradiotherapy for anal cancer (CORMAC-2): defining the outcomes from the CORMAC core outcome set.
- Authors: Samuel R, Knight SR, Adams R, Das P, Dorth J, Finch D, Guren MG, Hawkins MA, Moug S, Rajdev L, Sebag-Montefiore D, Renehan AG, Fish R, plus the CORMAC-2 collaborators
- Issue date: 2024 Dec
- Systematic review of outcome measures following chemoradiotherapy for the treatment of anal cancer (CORMAC).
- Authors: Fish R, Sanders C, Ryan N, der Veer SV, Renehan AG, Williamson PR
- Issue date: 2018 May
- Developing a core outcome set for interventions to improve discharge from mental health inpatient services: a survey, Delphi and consensus meeting with key stakeholder groups.
- Authors: Tyler N, Wright N, Grundy A, Waring J
- Issue date: 2020 May 12
- A core outcome set for childhood epilepsy treated with ketogenic diet therapy (CORE-KDT study): International parent and health professional consensus.
- Authors: Carroll JH, Cross JH, Hickson M, Williams E, Aldridge V, Collinson A
- Issue date: 2023 Apr